HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and Abuse
WASHINGTON--Medicare and Medicaid are hard pressed to stay ahead of profiteers bent on cheating the system administered by the Health Care Financing Administration (HCFA).
WASHINGTON--Medicare and Medicaid are hard pressed to stay aheadof profiteers bent on cheating the system administered by theHealth Care Financing Administration (HCFA).
Sarah F. Jaggar, director of health financing and policy issuesfor HCFA, testified before the House Subcommittee on Human Resourcesand Intergovernmental Relations that HCFA's fraud and abuse preventionprograms are weak.
She said that Medicare and Medicaid offer strong incentives forproviders to overprovide services, that HCFA has few controlsto detect questionable billing practices and too few limits onthe types of providers allowed to bill the federal agency, andthat there is little chance that profiteers will be prosecutedor will have to repay fraudulently obtained money.
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
